↓ Skip to main content

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Overview of attention for article published in New England Journal of Medicine, September 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
57 news outlets
blogs
4 blogs
policy
3 policy sources
twitter
216 X users
patent
7 patents
facebook
11 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
1760 Dimensions

Readers on

mendeley
1199 Mendeley
citeulike
1 CiteULike